NRG Therapeutics is a neuroscience-focused drug discovery company developing new medicines for neurodegenerative disorders. The company aims to restore mitochondrial function and slow or halt the progression of diseases such as Parkinson's and Amyotrophic Lateral Sclerosis (ALS).

NRG Therapeutics

AWARD FINALIST: We’re delighted to be recognised by Business Weekly newspaper for our progress in tackling some of the most important challenges in drug discovery research and human healthcare by leveraging breakthrough science in the field of #mitochondrial biology to identify new therapies to treat #neurodegenerative disorders such as #Parkinsons and Amyotrophic Lateral Sclerosis (#ALS)/Motor Neurone Disease (#MND).

Yesterday Business Weekly announced that we have been selected as a finalist in its annual awards that recognise and celebrate achievements of companies across the East of England region in any sector. As expected, many finalists are from the biotech sector, which is strongly represented in the region.

See the full shortlist of finalists here https://lnkd.in/ejim8hvh 

Tony Quested, Editor said ‘The competition has attracted a record entry in terms of numbers and the quality throughout the shortlist is also arguably the best we have ever seen.’

Winners will be announced during the gala dinner at Queens’ College on September 11 – good luck to all finalists. 

Read more about our research and pipeline here www.nrgtherapeutics.com 

#BioTech #DrugDiscovery #Award

Every year the The International Alliance of ALS/MND Associations celebrates 21 June as the global day of recognition of Amyotrophic Lateral Sclerosis (#ALS)/ Motor Neurone Disease (#MND) – a disease on the increase that affects people in every country of the globe. 

June 21 is the solstice and hopefully a turning point each year for progress in the search for the cause, treatment and, one day a cure, of ALS/MND. This year is the 10th anniversary of the memorable #icebucketchallenge. Remarkable progress made– but not enough.

At NRG we are energizing drug discovery in neurodegenerative diseases and advancing a pipeline of first-in-class brain-penetrant, oral small molecule drug candidates as potential disease modifying treatments based on breakthrough science in the field of mitochondrial biology. 

We are grateful for grant support from Innovate UK and, in partnership with lead applicant WEHI (Walter and Eliza Hall Institute of Medical Research) from FightMND, for our #MND #DrugDiscovery programme.

The goal for our inhibitors of the mitochondrial permeability transition pore (#mPTP) is to restore mitochondrial function and thereby slow or halt the progression of Parkinson’s, ALS/MND and eventually other #NeurodegenerativeDiseases. 

#ALSMNDWithoutBorders #neuroscience #Innovation

The final conference in our spring schedule! Our full founding team are crossing the pond to attend @BIO International Convention 3-6 June in San Diego. CEO Neil Miller, CSO Richard Rutter and COO Grant. Hawthorne will be networking and partnering, to meet with #biotech industry colleagues, investors and #Pharma partners.

Get in touch if you’d like to hear more about our pipeline of first-in-class brain-penetrant, oral small molecule inhibitors of the mitochondrial permeability transition pore (#mPTP) being developed to halt the progression of #Parkinson’s, #ALS (also known as motor neurone disease #MND) and eventually other CNS diseases.

Email – info@nrgtherapeutics.com

#DrugDiscovery #Biotech #Networking #NeurodegenerativeDiseases

Our CEO Neil Miller will be in London next week at OBN (UK) Ltd #BioTrinity 2024, April 23-24 presenting on a panel, and networking with colleagues in the #biotech industry and meeting with investors and partners.

Come along to the panel:
Neurodegenerative & Age-Related Diseases R&D Spotlight: Science Track 1, 13.30 – 15.00, April 24

We are proud of our work to develop disease modifying therapies for #NeurodegenerativeDiseases. 

Get in touch if you’d like to hear more about our pipeline of first-in-class brain-penetrant, oral small molecule inhibitors of the mitochondrial permeability transition pore (#mPTP) being developed to halt the progression of #Parkinson’s, #ALS (also known as motor neurone disease #MND) and eventually other CNS diseases.

Email – info@nrgtherapeutics.com

#DrugDiscovery #Biotech #Networking

It’s #WorldParkinsonsDay. NRG Therapeutics is passionate about developing new medicines that bring hope to the growing number of people worldwide living with debilitating neurodegenerative disorders including Parkinson’s.

We are leveraging breakthrough science in the field of mitochondrial biology to identify new therapeutic targets to treat neurodegenerative disorders. We are advancing a pipeline of potential first-in-class brain-penetrant, oral small molecule inhibitors of the mitochondrial permeability transition pore (#mPTP) with the aim of restoring mitochondrial function and slowing or halting the progression of Parkinson’s and ALS, also known as motor neurone disease (MND). 

Thank you to support from Parkinson's UK as investor and grant support from THE MICHAEL J FOX FOUNDATION FOR PARKINSON.

#DrugDiscovery #Neuroscience #NeurodegenerativeDisorders #Parkinsons

On World Health Organization World Health Day we highlight the health challenge of neurological diseases: an estimated 1 in 3 people will be affected by a neurological condition, the leading cause of illness and disability worldwide. Over 2% of persons over 65 years are estimated to have a neurodegenerative disease.

At NRG we are energizing drug discovery in neurodegenerative diseases and advancing a pipeline of first-in-class brain-penetrant, oral small molecule drug candidates as potential disease modifying treatments based on breakthrough science in the field of mitochondrial biology. The goal for our inhibitors of the mitochondrial permeability transition pore (#mPTP) is to restore mitochondrial function and thereby slow or halt the progression of Parkinson’s, #ALS (also known as motor neurone disease #MND) and eventually other neurodegenerative diseases.

#MyhealthMyRight

#DrugDiscovery #neuroscience #NeurodegenerativeDisorders #Innovation #WorldHealthDay

The time has arrived - we're off to San Francisco #JPM24 Neil Miller Richard Rutter - looking forward to meeting up with investors, industry partners and colleagues old and new. See you there!
#networking #drugdiscovery #neurodegenerativediseases

We are just four weeks away from the life science industry’s annual meetup  during the JP Morgan Healthcare conference in San Francisco. 

This year our leadership team Neil Miller Richard Rutter Grant. Hawthorne will all be attending to meet investors and partners to discuss the progress of our pipeline of first-in-class brain-penetrant, oral small molecule inhibitors of the mitochondrial permeability transition pore (#mPTP) as potential disease modifying treatments for neurodegenerative disorders. By restoring mitochondrial function our aim is to slow or halt the progression of #Parkinsons, #ALS (also known as motor neurone disease #MND) and eventually other CNS diseases.

Contact us to find our more or to meet up: info@nrgtherapeutics.com 

Learn about our breakthrough research: https://lnkd.in/ecUxRHYk 

#JPM24 #DrugDiscovery #neuroscience #NeurodegenerativeDisorders #Innovation #mitochondria

You still have time to vote for your chosen company #Genesis23 #BioNewsRound - as a finalist we would be honoured to be selected for your vote for our #Parkinson's programme. Helping is win is just a click away - 
https://lnkd.in/d6XQ79hB

thank you

With so much good news in our sector, we are delighted to have been selected as a finalists for this year's #Genesis #BioNewsRound #Award. Thanks One Nucleus.

We were selected for being awarded a Second $500K Grant from The Michael J. Fox Foundation for Parkinson's Research to Further Progress our #Parkinson’s Programme (after meeting the goals of our first grant).

We have discovered novel mitochondrial permeability transition pore (#mPTP) inhibitors that are small drug-like molecules, orally bioavailable and brain penetrant, and therefore have the potential for use in the treatment of chronic #NeurodegenerativeDisorders. The MJFF grant will support experiments to validate a novel mitochondrial drug target for Parkinson’s. 

Show your support for the progress we have made in the urgent quest to find disease modifying drugs for Parkinsons. You can read more detail here
https://lnkd.in/eps-ga3p

Voting is now open for everyone - to see more about the finalists and vote see https://lnkd.in/em68JA5M. 

We appreciate you vote.

news impact assignment basic	general
public peers	general	Sep 1, 2024 3:42 AM	370fee79
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Sep 1, 2024 3:42 AM	200dda67
translate crunchbase fundingrounds	general
peers	general	Sep 1, 2024 3:42 AM	bec0c621
news basic	general	Sep 1, 2024 3:42 AM	3aacdf60
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

NRGT

COM:NRGTHERAPEUTICS

NRG Therapeutics